“As API suppliers, we've been a little bit in the middle,” Gomes claims. “We see what is happening with our buyers who're generic or branded drug manufacturers, but we also see what is occurring with the earliest phase of the provision chain.Action two: Predict a set of potential/extending MRM pairs in step with the listing obtained in move�